$6,402.17 consulting Payment -- Regeneron Pharmaceuticals to Dr. Stephanie King

Regeneron Pharmaceuticals Pays Allergy & Immunology Specialist $6,402.17 for Consulting

This page provides a detailed analysis of a $6,402.17 consulting payment from Regeneron Pharmaceuticals to Dr. Stephanie King. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$6,402.17
Payment Typeconsulting
Payment NatureConsulting Fee
Pharmaceutical CompanyRegeneron Pharmaceuticals
PhysicianDr. Stephanie King
NPI Number1460530312
Physician SpecialtyAllergy & Immunology
LocationRaleigh, NC
Date of Payment2024-05-06
Conflict AssessmentLow -- Routine

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Regeneron Pharmaceuticals made a $6.4K consulting payment to Stephanie King, a Allergy & Immunology specialist in Raleigh, NC. Regeneron Pharmaceuticals paid Dr. Stephanie King $6,402.17 for consulting services on May 6, 2024. The payment was for consulting fees, indicating a professional service engagement. Dr. King's specialty is Allergy & Immunology, and the payment was made in Raleigh, NC.

Patient Guidance: What This Payment Means for You

This payment represents compensation for professional consulting services provided to a pharmaceutical company. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Consulting fees are common in the pharmaceutical industry, but the specific amount and nature of the engagement should be reviewed in the context of typical compensation for Allergy & Immunology specialists.

Regulatory Context: Sunshine Act Requirements

This payment is reported under the Sunshine Act, which requires disclosure of payments made by drug and medical device manufacturers to physicians and teaching hospitals.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding consulting Payments

Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.

Frequently Asked Questions About This Payment

What was this $6.4K payment for?

This was a consulting payment of $6.4K from Regeneron Pharmaceuticals to Stephanie King, categorized as "Consulting Fee". The payment was reported under the Sunshine Act (CMS Open Payments).

Does Stephanie King accept pharmaceutical money?

Yes, Stephanie King received this $6.4K payment from Regeneron Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Stephanie King's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this consulting payment?

A consulting payment of $6.4K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Allergy & Immunology?

To compare this payment against Allergy & Immunology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Allergy & Immunology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Stephanie King's relationship with Regeneron Pharmaceuticals?

The payment amount is a specific figure, $6,402.17. This $6.4K consulting payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Allergy & Immunology?

The payment type is explicitly 'consulting'.

What should patients do after learning about this payment?

This payment represents compensation for professional consulting services provided to a pharmaceutical company.

What else should I know about this consulting payment?

The payment date is recent, May 6, 2024.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.